Policies to set up capital to help domestic medical devices enter the golden development period

Recently, the National Medical Insurance Administration issued the "Agreement of the National Medical Security Bureau on the Suggestions No. 4955 of the Fifth Session of the 13th National People's Congress". The "Answer" states that because the clinical use of innovative medical devices is not yet mature and the amount of use is temporarily difficult to estimate, it is difficult to implement the method of bringing. In addition to the concentrated volume procurement, a certain market provides space for innovative products to develop markets.

The industry believes that this statement conveys positive signals to the market, which is expected to stabilize market expectations and enhance domestic enterprises' enthusiasm for the development of innovative medical devices.

Taken together, my country has become the second largest medical device market in the world, but the overall strength of the industry is not matched with the market size. In the top 50 global medical devices, there are no companies from China. At present, the medical device industry is still facing the situation of key core technologies and high -end equipment, and enterprises are generally concentrated in the competition in the low -end market competition.

In order to make up for the shortcomings of my country's high -end medical equipment, accelerate key core technology research, and break through the bottlenecks of technical equipment, in recent years, a number of support policies have been introduced one after another. For example, in 2018, the State Drug Administration was amended and released the "Special Examination Procedures for Innovation Medical Device"; the "Regulations on the Supervision and Administration of Medical Device Supervision and Administration" implemented from June 1, 2021 proposed to give priority to review and approval of innovative medical devices. As of September 5 this year, the State Drug Administration has approved 176 innovative medical device registration and listed, mainly involving cardiovascular intervention, IVD, medical image, peripheral intervention, surgical robot, auxiliary diagnostic software, and tumor treatment.

The "Medical Equipment Industry Development Plan (2021-2025)" released by the Ministry of Industry and Information Technology proposes that by 2025, six to 8 domestic equipment companies will promote the top 50 global medical device industry. This means that domestic companies have broad growth space.

While the policy continues to encourage the innovation of the medical device field, the capital market's support for this track has continued to heat up. In June 2022, the Shanghai Stock Exchange issued the implementation of the "Shanghai Stock Exchange Exchange Science and Technology Innovation Board Listing and Listing Review Regulations No. 7 -Medical Device Enterprise Applicable Fifth Listing Standard", which will use the fifth set of listing standards for the science and technology board The scope is widened to medical device enterprises, and it further creates a good capital environment for hard technology medical device companies that have not yet formed a certain income during the R & D stage. At present, the microelectronics of medical device enterprises has achieved the listing of the "Fifth Set of Science and Technology Board Standards". In the future, more companies will use this listing standard to smoothly achieve financing.

Policies and capital assistance, medical device tracks have entered the golden development period, enterprises can expand their skills with their strength, move towards the high -end industry chain, and develop to world -class outstanding enterprises. (Zhang Min)

- END -